TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36357273

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 33608260

Group type: COMPARATOR
Intervention: EXER intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: CBT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: EXER1CBT intervention
Number of subjects: 0
Study: 33109331

Group type: EXPERIMENTAL
Intervention: Early surgical fixation using Conformité Européenne‐marked headless compression screws.
Number of subjects: 439

Group type: COMPARATOR
Intervention: Below-elbow cast immobilisation for 6-10 weeks and urgent fixation of confirmed non-union.
Number of subjects: 439
Study: 35986465

Group type: EXPERIMENTAL
Intervention: Phos‐Flur gel (study group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Deionized water (control group)
Number of subjects: 56
Study: 33162800

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Volume-Guaranteed Ventilation (PCV-VG)
Number of subjects: 60
Study: 34332606

Group type: EXPERIMENTAL
Intervention: Incident ROA at knee level
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: Incident ROA at patient level
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: Female
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: Less ROM
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: KL grade 1 at baseline
Number of subjects: 1295
Study: 33144594

Group type: EXPERIMENTAL
Intervention: Walking together with self-selected turns and speed changes
Number of subjects: 2
Study: 32297054

Group type: EXPERIMENTAL
Intervention: Laparoscopically guided TAP block with 10 ml of 0.25% bupivacaine at each of the four sites
Number of subjects: 100

Group type: COMPARATOR
Intervention: Port site infiltration with 0.25% bupivacaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Laparoscopically guided TAP block
Number of subjects: 100
Study: 33876562

Group type: EXPERIMENTAL
Intervention: Home-based exercise (150 min/week)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Home-based exercise (120 min/week)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (regular lifestyle)
Number of subjects: 98
Study: 34339951

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 8 U/kg
Number of subjects: 350

Group type: COMPARATOR
Intervention: IncobotulinumtoxinA 2 U/kg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 6 U/kg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (all doses)
Number of subjects: 350
Study: 32321385

Group type: EXPERIMENTAL
Intervention: 8-week endurance training
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 8-week resistance training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 52
Study: 35019975

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 1552
Study: 33687487

Group type: EXPERIMENTAL
Intervention: PB-119 75 μg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: PB-119 150 μg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: PB-119 200 μg
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 34802339

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Community-based HIV testing services (HTS)
Number of subjects: 577

Group type: COMPARATOR
Intervention: HTS
Number of subjects: 577
Study: 34477813

Group type: EXPERIMENTAL
Intervention: Multiplex ligand‐dependent probe amplification (MLPA)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: ΔIKZF1 alterations (including DN or loss‐of‐function lesions)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: IKZF1plus genotype
Number of subjects: 498
Study: 35853272

Group type: EXPERIMENTAL
Intervention: Pre-operative sublingual 400mcg misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34387949

Group type: EXPERIMENTAL
Intervention: Exercise‐induced hypoalgesia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 19

Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 19
Study: 32353822

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 35704338

Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes (0.4 mg/g nicotine)
Number of subjects: 286
Study: 32669641

Group type: EXPERIMENTAL
Intervention: 3D-printing
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 3D-image
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control
Number of subjects: 61
Study: 32661291

Group type: EXPERIMENTAL
Intervention: 24-h Physical Activity Recall (24PAR)
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: SenseWear Armband (SWA)
Number of subjects: 1247

Group type: COMPARATOR
Intervention: SWA vs 24PAR
Number of subjects: 1247
Study: 32520577

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion in LPS-challenged volunteers
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Higher norepinephrine infusion rates in patients
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: β-blocker use in patients
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 195
Study: 35575754

Group type: EXPERIMENTAL
Intervention: OpenPose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: MSRA
Number of subjects: 14
Study: 33716112

Group type: EXPERIMENTAL
Intervention: Resistance training group (n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 17
Study: 32143737

Group type: EXPERIMENTAL
Intervention: Early continuous Kangaroo Mother Care (KMC) within 24 hours of admission
Number of subjects: 392

Group type: COMPARATOR
Intervention: Standard care (incubator or radiant heater with KMC when clinically stable at > 24 hours of admission)
Number of subjects: 392
Study: 35833783

Group type: EXPERIMENTAL
Intervention: napabucasin plus paclitaxel
Number of subjects: 714

Group type: COMPARATOR
Intervention: placebo plus paclitaxel
Number of subjects: 714
Study: 33263447

Group type: EXPERIMENTAL
Intervention: HXLPE/VitE acetabular cups
Number of subjects: 62

Group type: COMPARATOR
Intervention: UHMWPE acetabular cups
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: HXLPE/VitE and UHMWPE cups
Number of subjects: 62
Study: 35838942

Group type: EXPERIMENTAL
Intervention: Melatonin (0.3 mg/kg for < 10 kg, 3 mg for 10-15 kg, 6 mg for > 15 kg)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Triclofos (50 mg/kg, max 1 g for 6 mo to 11 y; 2 g for 11 to 18 y)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 228

Group type: COMPARATOR
Intervention: Triclofos
Number of subjects: 228
Study: 34858912

Group type: EXPERIMENTAL
Intervention: CHE households
Number of subjects: 0
Study: 36104714

Group type: EXPERIMENTAL
Intervention: Preoperative echocardiography
Number of subjects: 4514

Group type: COMPARATOR
Intervention: Control group (no preoperative echocardiography)
Number of subjects: 4514
Study: 34370612

Group type: EXPERIMENTAL
Intervention: Nonimmersive virtual reality (VR) intervention associated with conventional therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 22
Study: 32898379

Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency Ablation (CRFA)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 175
Study: 35351707

Group type: EXPERIMENTAL
Intervention: Individual goal-based plan based on nursing theory
Number of subjects: 110
Study: 36360667

Group type: EXPERIMENTAL
Intervention: Motivational program (yoga training)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study: 32110003

Group type: EXPERIMENTAL
Intervention: Lifestyle Matters intervention
Number of subjects: 13
Study: 35999816

Group type: EXPERIMENTAL
Intervention: Patient engagement strategies including bi-weekly meetings, newsletters, and educational materials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-driven initiative to draft letters sharing personal stories.
Number of subjects: 0
Study: 35756427

Group type: EXPERIMENTAL
Intervention: Comfort care
Number of subjects: 118

Group type: COMPARATOR
Intervention: WNNM algorithm
Number of subjects: 118
Study: 32555011

Group type: EXPERIMENTAL
Intervention: Patterned feeding experience involving a tactile component (touch and/or holding) during feedings
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual feeding care
Number of subjects: 120
Study: 36306132

Group type: EXPERIMENTAL
Intervention: 2.4 g intravenous casirivimab and imdevimab
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: 8.0 g intravenous casirivimab and imdevimab
Number of subjects: 657

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 657
Study: 34519801

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy (paclitaxel 175 mg/m2 and cisplatin 75 mg/m2)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (paclitaxel 175 mg/m2 and cisplatin 75 mg/m2)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 596

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 596
Study: 35527346

Group type: EXPERIMENTAL
Intervention: Radio-guided occult lesion localisation using iodine-125 (ROLLIS)
Number of subjects: 659
Study: 33221561

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 138

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 138
Study: 35886524

Group type: EXPERIMENTAL
Intervention: Biomimetic hydroxyapatite toothpaste
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste (1450 ppm)
Number of subjects: 40
Study: 33783104

Group type: EXPERIMENTAL
Intervention: Family Check‐Up 4 Health (FCU4Health) program (N = 141)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care plus information (N = 99)
Number of subjects: 240
Study: 32454794

Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment
Number of subjects: 442

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 442
Study: 35973655

Group type: EXPERIMENTAL
Intervention: Peanut allergen powder‐dnfp (PTAH)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 34510911

Group type: EXPERIMENTAL
Intervention: No-touch technique
Number of subjects: 2655

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 2655
Study: 35377447

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lanraplenib 30 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tirabrutinib 40 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 33986043

Group type: EXPERIMENTAL
Intervention: 5-hour game jam (1-hour lecture + 4-hour game creation and play session)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1-hour conventional lesson + 4-hour study session of selected readings
Number of subjects: 79
Study: 35329211

Group type: EXPERIMENTAL
Intervention: Weekly content with customised behaviour change techniques (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-time and non-customised delivery of food-related international guidelines (comparison group)
Number of subjects: 0
Study: 33251659

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study: 35011103

Group type: EXPERIMENTAL
Intervention: Loigolactobacillus coryniformis K8 CECT 5711
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 32667902

Group type: EXPERIMENTAL
Intervention: Saline consumption (423 mL of normal saline, sodium 154 mmol/L)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no saline consumption)
Number of subjects: 24
Study: 33622669

Group type: EXPERIMENTAL
Intervention: 800 mg TTP399
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 37458867

Group type: EXPERIMENTAL
Intervention: 3200 × 5
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 3200 × 10
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 128
Study: 33464300

Group type: EXPERIMENTAL
Intervention: Atabecestat 25 mg
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Atabecestat (5 mg and 25 mg)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Follow-up after stopping treatment
Number of subjects: 557

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study: 32601653

Group type: EXPERIMENTAL
Intervention: Health literacy program (18-week duration)
Number of subjects: 22
Study: 35584268

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection with splint (40 mg methylprednisolone + 0.5 ml lidocaine, splint worn full time for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Corticosteroid injection without splint (40 mg methylprednisolone + 0.5 ml lidocaine)
Number of subjects: 60
Study: 34315722

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 60
Study: 35027324

Group type: EXPERIMENTAL
Intervention: HAI-ox with FOLFOX + targeted therapy or FOLFOXIRI + bevacizumab
Number of subjects: 348

Group type: COMPARATOR
Intervention: Systemic oxaliplatin with FOLFOX + targeted therapy or FOLFOXIRI + bevacizumab
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: HAI-ox
Number of subjects: 348

Group type: COMPARATOR
Intervention: Systemic oxaliplatin
Number of subjects: 348
Study: 34271948

Group type: EXPERIMENTAL
Intervention: Multifactorial intensive therapy (MT)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Standard-of-Care (SoC)
Number of subjects: 395
Study: 35437101

Group type: EXPERIMENTAL
Intervention: Morning exercise (8am-11am)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Afternoon exercise (5pm-8pm)
Number of subjects: 19
Study: 35274344

Group type: EXPERIMENTAL
Intervention: Home-based oral exercises (tongue-strengthening, oral diadochokinesis, mouth-opening exercises) for 3 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Advice on oral health care (Control group)
Number of subjects: 22
Study: 34057643

Group type: EXPERIMENTAL
Intervention: Flavonoids plus placebo (G3)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Metronidazole plus flavonoids (G4)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Metronidazole plus placebo (G2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Double-placebo (G1)
Number of subjects: 68
Study: 36191453

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 34769711

Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation
Number of subjects: 20
Study: 32513161

Group type: EXPERIMENTAL
Intervention: MOVEdiabetes programme (PA consultations, pedometers, WhatsApp messages)
Number of subjects: 232
Study: 34652335

Group type: EXPERIMENTAL
Intervention: Lower limb resistance training (RT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Concurrent training (CT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intermittent sprint protocol (ISP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All exercise conditions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 10
Study: 34936272

Group type: EXPERIMENTAL
Intervention: Wangbuliuxing decoction (oral administration, twice a day for 7 days) combined with massage at breast and acupoint (Zhongfu [LU 1], Yunmen [LU 2], Danzhong [CV 17], 2 min per acupoint, twice a day for 7 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine nursing (control group)
Number of subjects: 120
Study: 36435917

Group type: EXPERIMENTAL
Intervention: Sutureless deep sclerectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional deep sclerectomy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 32694376

Group type: EXPERIMENTAL
Intervention: HVREX (exercise hypoxic ventilatory response)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HVRREST (rest hypoxic ventilatory response)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10-km cycling TT in hypoxic gas mixture (FiO2 = 0.16)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10-km cycling TT in room air (FiO2 = 0.21)
Number of subjects: 16
Study: 32191129

Group type: EXPERIMENTAL
Intervention: Increasing sample size or replacing subjects who drop out
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attrition of subjects in a cohort design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attrition of clusters
Number of subjects: 0
Study: 35459233

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 29
Study: 35315622

Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Magnesium sulfate infusion
Number of subjects: 80
Study: 33586143

Group type: EXPERIMENTAL
Intervention: Eculizumab (maintenance dose = 1,200 mg/2 weeks)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (from PREVENT)
Number of subjects: 137
Study: 32483161

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 496
Study: 34470506

Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 102
Study: 35002228

Group type: EXPERIMENTAL
Intervention: BMMC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Co-infusion of BMMC and ADSC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 20
Study: 35724559

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (tVNS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 32660542

Group type: EXPERIMENTAL
Intervention: Moxidectin (24 μg/kg) for four or six monthly doses
Number of subjects: 6

Group type: COMPARATOR
Intervention: Heartgard® Plus (ivermectin/pyrantel) for six monthly doses
Number of subjects: 6

Group type: COMPARATOR
Intervention: Interceptor® Plus (milbemycin oxime/praziquantel) for six monthly doses
Number of subjects: 6
Study: 36400376

Group type: EXPERIMENTAL
Intervention: EC skin test (ECST)
Number of subjects: 1085

Group type: COMPARATOR
Intervention: TST (tuberculin skin test)
Number of subjects: 1085

Group type: COMPARATOR
Intervention: T-SPOT.TB
Number of subjects: 1085
Study: 33180306

Group type: EXPERIMENTAL
Intervention: One-level RDL reductions achieved by 84% of patients at the end of treatment; 84.9% maintained reduction at 3-year follow-up.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Two-level RDL reductions achieved by 68% of patients at the end of treatment; 77.7% maintained reduction at 3-year follow-up.
Number of subjects: 1500
Study: 32968194

Group type: EXPERIMENTAL
Intervention: Occupational physical activity
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Sports physical activity
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Leisure time/commuting physical activity
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 252
Study: 35617452

Group type: EXPERIMENTAL
Intervention: 35% glycolic acid (GA) applied once every fortnight for a total of three times
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adapalene gel applied every night (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 35% glycolic acid (GA)
Number of subjects: 30
Study: 34471992

Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg every 4 weeks (Q4W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Secukinumab 300 mg (weekly until Week 4, then Q4W)
Number of subjects: 0
Study: 35853465

Group type: EXPERIMENTAL
Intervention: Midwifery counseling with spiritual content
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 35815097

Group type: EXPERIMENTAL
Intervention: Structured lifestyle counselling sessions during pregnancy and postpartum
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Routine prenatal care (Control Group)
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Dietary supplementation (DHA, iron, vitamin D)
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Higher educational level, advanced age, primiparity, vegetarian diet
Number of subjects: 2099
Study: 33290813

Group type: EXPERIMENTAL
Intervention: Heparin locking
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (SQH) 7,500 units TID
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (SQH) 5,000 units
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (SQH) 7,500 units vs 5,000 units
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Systemic anticoagulation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Higher D-dimer levels
Number of subjects: 48
Study: 35994096

Group type: EXPERIMENTAL
Intervention: Inhibitory control training (3 sessions)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waitlist control group (no training)
Number of subjects: 61
Study: 32495306

Group type: EXPERIMENTAL
Intervention: Culturally tailored education intervention to promote physical activity and reduce salt intake, conducted through two educational sessions with follow-up at 3 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both intervention and control groups.
Number of subjects: 0
Study: 32536366

Group type: EXPERIMENTAL
Intervention: Weighted metal chain blanket
Number of subjects: 120

Group type: COMPARATOR
Intervention: Light plastic chain blanket
Number of subjects: 120